These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9032592)

  • 1. [Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders].
    Sawae Y; Niho Y; Okamura T; Gondo H; Kozuru M; Uike N; Muta K; Goto T; Suehiro Y; Kumakawa M; Nishimura J; Yufu Y; Ishikura H; Yamashita S; Hisano S; Morioka E; Nakajima H; Shibuya T; Yamasaki K; Harada N; Asayama R; Hayashi S; Akashi K; Suematsu E; Kawasaki C
    Jpn J Antibiot; 1996 Dec; 49(12):1049-61. PubMed ID: 9032592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy with imipenem/cilastatin for severe infections accompanied by malignant hematological disorders].
    Fujii Y; Inoue Y; Hiroshige Y; Kaku K; Kaneko T
    Jpn J Antibiot; 1993 Mar; 46(3):259-68. PubMed ID: 8510323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative study of imipenem/cilastatin sodium BID vs QID in the treatment of infections associated with hematopoietic disorders].
    Sawae Y; Niho Y; Okamura T; Murakawa M; Teshima T; Fujisaki T; Ikeda K; Kozuru M; Uike N; Katsuno M
    Jpn J Antibiot; 1994 Oct; 47(10):1318-28. PubMed ID: 7807693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic evaluation of imipenem/cilastatin sodium for bacterial infections in patients with hematological diseases].
    Sawae Y; Niho Y; Harada M; Shibuya T; Okamura T; Asano Y; Taniguchi S; Murakawa M; Toyoshima T; Kozuru M
    Jpn J Antibiot; 1992 Feb; 45(2):123-35. PubMed ID: 1613965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of a combination treatment using imipenem/cilastatin sodium with G-CSF on infections in neutropenic patients with hematological malignancies].
    Sawada H; Sasada M; Tajima M; Yamamoto K; Yasuda N; Omori S; Yumoto Y; Ishibashi T; Okada H; Suzuki T
    Jpn J Antibiot; 1995 Feb; 48(2):271-7. PubMed ID: 7538179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders].
    Tsuda S; Kuzuyama Y; Nakai H; Seriu T; Takashima T; Tanaka S; Horiike S; Taniwaki M; Misawa S; Kashima K
    Jpn J Antibiot; 1993 Feb; 46(2):171-83. PubMed ID: 8331778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders].
    Tsukada T; Katayama N; Kageyama S; Nishikawa M; Kobayashi T; Deguchi K; Shirakawa S; Minami N
    Jpn J Antibiot; 1990 Dec; 43(12):2087-93. PubMed ID: 2086823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections].
    Takamoto M; Ishibashi T; Toyoshima H; Tanaka H; Tamaru N; Watanabe K; Yoshida M; Tokunaga N; Ichikawa Y; Oizumi K
    Jpn J Antibiot; 1994 Sep; 47(9):1131-44. PubMed ID: 7990255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group].
    Fujii R; Sakata H; Inyaku F; Fujita K; Maruyama S; Yoshioka H; Hashira S; Tajima T; Nakazawa S; Sato H
    Jpn J Antibiot; 1989 Apr; 42(4):953-72. PubMed ID: 2671429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of imipenem/cilastatin sodium against infections in compromised children (malignancy, hematological disease, collagen disease)].
    Nakano T; Itoh M; Sakurai M
    Jpn J Antibiot; 1992 Aug; 45(8):1016-22. PubMed ID: 1433890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of imipenem/cilastatin sodium as a second line regimen in severe infections associated with hematologic disorders].
    Tsuda S; Nakai H; Murakami T; Seryu S; Takashima T; Tanaka S; Nakagawa H; Nishigaki H; Okuda T; Nishida K
    Jpn J Antibiot; 1991 Aug; 44(8):886-98. PubMed ID: 1920814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
    Iwai N; Nakamura H; Miyazu M; Kasai K; Taneda Y
    Jpn J Antibiot; 1989 May; 42(5):1087-101. PubMed ID: 2746858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer].
    Yoshida M; Watanabe K; Tanaka H; Senju S; Ishibashi T; Takamoto M; Oizumi K; Kondo Y; Shigematsu H; Ohno T; Ichikawa Y; Hara N; Mitsuyama T; Nakanishi Y; Yamada H; Kuroki S; Motohiro A; Ueda H; Kusano T; Hiratsuka M; Nikaido Y; Kido M; Miyahara T; Ninomiya K; Naoe H
    Jpn J Antibiot; 1997 Jan; 50(1):22-38. PubMed ID: 9059911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders].
    Hotta T; Morishima Y; Saito H; Kodera Y; Hirabayashi N; Tanaka M; Mizuno H; Suzuki H; Kato Y; Morishita Y
    Jpn J Antibiot; 1991 May; 44(5):515-28. PubMed ID: 1880931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imipenem/cilastatin sodium and other beta-lactams for respiratory tract infections: clinical benefit and treatment days for cure].
    Oizumi K; Rikimaru T; Shiraishi T; Motohiro A; Yoshida M; Watanabe K; Maruyama R; Ishibashi T; Kitahara Y; Kido M; Yoshii C; Hara N; Ikeda A; Yamada H; Ninomiya K; Matsuzaki Y; Ichinose Y; Namba K; Kodama T; Kunitake R; Miyazaki N; Abe K; Matsunaga R; Ide H; Kamae I
    Jpn J Antibiot; 1999 Jan; 52(1):1-15. PubMed ID: 10202683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of imipenem/cilastatin sodium in infectious complications of hematological malignancies. Tohkai Research Group on Infections in Hematological Disorders].
    Naito K; Kobayashi M; Okumura M; Ikeda Y; Mitomo Y; Oguri T; Tanaka M; Ohara K; Kodera Y; Ohno R
    Jpn J Antibiot; 1990 Aug; 43(8):1371-80. PubMed ID: 2283705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer.
    Matsui K; Masuda N; Takada M; Kusunoki Y; Fukuoka M
    Jpn J Clin Oncol; 1991 Dec; 21(6):428-34. PubMed ID: 1805048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates].
    Azagami S; Kusumoto Y; Oikawa T; Osano M; Shiro H; Shirai Y; Nakamura M
    Jpn J Antibiot; 1988 Nov; 41(11):1704-14. PubMed ID: 3210302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem/cilastatin as secondary therapy for bacterial infections.
    Kono K; Onuki K; Tohara S; Takeda S
    Clin Ther; 1991; 13(4):448-56. PubMed ID: 1933995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of imipenem/cilastatin sodium in the perinatal period].
    Yamamoto T; Yasuda J; Kanao M; Okada H
    Jpn J Antibiot; 1988 Nov; 41(11):1792-6. PubMed ID: 3210310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.